Chad J. Swanson

Follow

Generating author description...

All published works
Action Title Year Authors
+ PDF Chat Lecanemab for Patients With Early Alzheimer Disease 2023 Donald A. Berry
Shobha Dhadda
Michio Kanekiyo
David Li
Chad J. Swanson
Michael C. Irizarry
Lynn D. Kramer
Scott Berry
+ ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease 2023 Lawrence S. Honig
Jerome Barakos
Shobha Dhadda
Michio Kanekiyo
Larisa Reyderman
Michael C. Irizarry
Lynn D. Kramer
Chad J. Swanson
Marwan Sabbagh
+ Subcutaneous Dose Selection of Lecanemab for Treatment of Subjects with Early Alzheimer’s Disease (EAD) 2022 Seiichi Hayato
Sumit Rawal
Osamu Takenaka
Ishani Landry
Peter D. W. Boyd
Jagadeesh Aluri
Brian A. Willis
Chad J. Swanson
Sanae Yasuda
Ziad Hussein
+ Derivation and evaluation of signatures using plasma β‐amyloid and pTau‐181 for brain amyloid‐β detection 2022 Viswanath Devanarayan
Shobha Dhadda
Akihiko Koyama
Chad J. Swanson
Harald Hampel
Michael C. Irizarry
Lynn D. Kramer
+ Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open‐Label Extension (OLE). 2022 Ishani Landry
Michio Kanekiyo
Jagadeesh Aluri
David Jianjun Li
Ziad Hussein
Larisa Reyderman
Shobha Dhadda
Chad J. Swanson
Michael C. Irizarry
Lynn D. Kramer
+ Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease 2022 Seiichi Hayato
Osamu Takenaka
Sree Harsha Sreerama Reddy
Ishani Landry
Larisa Reyderman
Akihiko Koyama
Chad J. Swanson
Sanae Yasuda
Ziad Hussein
+ Plasma Aβ 42:40 ratio tracks with changes in brain amyloid PET SUVr in the core and open label extension of the phase 2 proof of concept study ban2401‐g000‐201 following treatment with lecanemab in subjects with early Alzheimer’s disease 2021 Chad J. Swanson
Michio Kanekiyo
June Kaplow
Shobha Dhadda
Michael C. Irizarry
Akihiko Koyama
David Jianjun Li
David Verbel
Robert J. Gordon
Helena Heanue‐Travers
+ PDF Chat A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer’s disease 2020 Chad J. Swanson
Yong Zhang
Shobha Dhadda
Jinping Wang
June Kaplow
Heather Bradley
Martin Rabe
Robert Lai
Robert J. Gordon
Lynn D. Kramer
+ PDF Chat A preliminary account of ARIA‐E in the ongoing open‐label extension phase of BAN2401‐G000‐201 in subjects with early Alzheimer’s disease 2020 Chad J. Swanson
Robert Lai
Tanya Bogoslovsky
Heather Bradley
Martin Rabe
Yong Zhang
Lynn D. Kramer
+ BAN2401 In Early Alzheimer's Disease: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety And Efficacy (1567) 2020 Shau Yu Lynch
Michael C. Irizarry
Shobha Dhadda
Yong Zhang
Jinping Wang
Tanya Bogoslovsky
Larisa Reyderman
June Kaplow
Heather Bradley
Martin Rabe
+ Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease (1330) 2020 Chad J. Swanson
Yong Zhang
Shobha Dhadda
Jinping Wang
June Kaplow
Heather Bradley
Martin Rabe
Keiichiro Totsuka
Robert Lai
Robert J. Gordon
+ A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with BAN2401, an Anti-Aβ Protofibril Antibody 2020 Chad J. Swanson
Yong Zhang
Shobha Dhadda
Jinping Wang
June Kaplow
Robert Lai
Lars Lannfelt
Heather Bradley
Martin Rabe
Akihiko Koyama
+ P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES 2019 Edgar Schuck
Larisa Reyderman
Seiichi Hayato
Osamu Takenaka
Chad J. Swanson
Robert Lai
Ziad Hussein
Jim Ferry
+ Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease 2016 Andrew Satlin
Jinping Wang
Veronika Logovinsky
Scott Berry
Chad J. Swanson
Shobha Dhadda
Donald A. Berry
Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease 2016 Andrew Satlin
Jinping Wang
Veronika Logovinsky
Scott Berry
Chad J. Swanson
Shobha Dhadda
Donald A. Berry
2
+ Bayesian clinical trials 2006 Donald A. Berry
2
+ A Bayesian Dose-Finding Design Adapting to Efficacy and Tolerability Response 2012 S. Krishna Padmanabhan
Scott Berry
Vladimir Dragalin
Michael Krams
1
+ Viewpoints on the FDA Draft Adaptive Designs Guidance from the PhRMA Working Group 2010 Paul Gallo
Keaven M. Anderson
Christy Chuang‐Stein
Vladimir Dragalin
Brenda Gaydos
Michael Krams
JosÊ CirĹ́aco Pinheiro
1
+ Improving Alzheimer's disease phase II clinical trials 2012 Barry Greenberg
MarĂ­a C. Carrillo
J. Michael Ryan
Michael Gold
Kim P. Gallagher
Michael Grundman
Robert Berman
T. Ashwood
Eric Siemers
1
+ Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group 2006 Paul Gallo
Christy Chuang‐Stein
Vladimir Dragalin
Brenda Gaydos
Michael Krams
JosÊ CirĹ́aco Pinheiro
1
+ Missing Data, Imputation, and the Bootstrap 1994 Bradley Efron
1
+ Adaptive clinical trials in oncology 2011 Donald A. Berry
1
+ A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug 2010 Scott Berry
Walter Spinelli
Gary S. Littman
John Z. Liang
Parvin Fardipour
Donald A. Berry
Roger Lewis
Michael Krams
1
+ Adaptive, group sequential and decision theoretic approaches to sample size determination 2006 Cyrus R. Mehta
Nitin R. Patel
1
+ Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models 2011 Martin Bergstrand
Andrew C. Hooker
Johan Wallin
Mats O. Karlsson
1
+ Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics 2009 Leonid Gibiansky
Ekaterina Gibiansky
1
+ Adaptive Clinical Trials 2012 William J. Meurer
Roger Lewis
Donald A. Berry
1
+ Interim Analysis in Clinical Trials: The Role of the Likelihood Principle 1987 Donald A. Berry
1
+ Sample size and the probability of a successful trial 2006 Christy Chuang‐Stein
1
+ The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research 2015 Donald A. Berry
1
+ Emerging innovations in clinical trial design 2015 DA Berry
1
+ Charting a path toward combination therapy for Alzheimer’s disease 2014 Diane Stephenson
D.F. Perry
Cynthia Bens
Lisa J. Bain
Donald A. Berry
Michael Krams
Reisa A. Sperling
David M. Dilts
Johan Luthman
Debra Hanna
1
+ Science and Statistics 1976 George E. P. Box
1
+ PDF Chat The need for thorough phase II studies in medicines development for Alzheimer’s disease 2015 Julian Gray
David Fleet
Bengt Winblad
1
+ Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. 2001 Yoshitaka Yano
Stuart L. Beal
Lewis B. Sheiner
1
+ PDF Chat The Prevention and Treatment of Missing Data in Clinical Trials 2010 National Research Council
1
+ PDF Chat Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology 2019 Gaurav Bajaj
Satyendra Suryawanshi
Amit Roy
Manish Gupta
1
+ P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES 2019 Edgar Schuck
Larisa Reyderman
Seiichi Hayato
Osamu Takenaka
Chad J. Swanson
Robert Lai
Ziad Hussein
Jim Ferry
1
+ PDF Chat Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease 2021 Kumar Kandadi Muralidharan
Xiao Tong
Kenneth G. Kowalski
Raj Rajagovindan
Lin Lin
Samantha Budd Haberlain
Ivan Nestorov
1
+ Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease 2022 Seiichi Hayato
Osamu Takenaka
Sree Harsha Sreerama Reddy
Ishani Landry
Larisa Reyderman
Akihiko Koyama
Chad J. Swanson
Sanae Yasuda
Ziad Hussein
1
+ ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease 2023 Lawrence S. Honig
Jerome Barakos
Shobha Dhadda
Michio Kanekiyo
Larisa Reyderman
Michael C. Irizarry
Lynn D. Kramer
Chad J. Swanson
Marwan Sabbagh
1
+ PDF Chat Phase II Trial Design with Bayesian Adaptive Randomization and Predictive Probability 2012 Guosheng Yin
Nan Chen
J. Jack Lee
1
+ Bayesian Adaptive Methods for Clinical Trials 2010 Scott Berry
Bradley P. Carlin
J. Jack Lee
Peter MĂźller
1
+ Bayesian Adaptive Methods for Clinical Trials 2010 Cody Hamilton
1